Liver Cancer Trial, Recruiting (NCT06405321)

Liver Cancer Trial, Recruiting NCT06405321 Sponsor: Guangxi Medical University Condition: Liver Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06405321 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Liver Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with hepatocellular carcinoma (a type of liver cancer), either confirmed by a tissue sample or by clinical assessment.
People who received certain treatments before surgery as their first treatment, such as chemotherapy delivered directly to the liver's blood supply, a procedure to block blood flow to the tumour while delivering medication, targeted therapy drugs, immunotherapy drugs, or radiotherapy.
People whose general physical health and ability to carry out daily activities is rated as fully active or restricted in strenuous activity but able to do light work (confirm with trial site).
People whose liver function falls within a specific scoring range indicating reasonably well-preserved liver function (confirm with trial site).

Who may not be able to join:

People who have had another type of cancer within the past 5 years.
People whose medical records are incomplete.
People who have been followed up by their medical team for less than 3 months.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 6 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jian-Hong Zhong, Ph.D, Guangxi Medical University Cancer Hospital

Phone: +86 771 5301253

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06405321

Sponsor: Guangxi Medical University

Phase: Not Applicable

Status: Recruiting

Condition: Liver Cancer

Trial contact: +86 771 5301253

More information: https://clinicaltrials.gov/study/NCT06405321

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with hepatocellular carcinoma (a type of liver cancer), either confirmed by a tissue sample or by clinical assessment.
People who received certain treatments before surgery as their first treatment, such as chemotherapy delivered directly to the liver's blood supply, a procedure to block blood flow to the tumour while delivering medication, targeted therapy drugs, immunotherapy drugs, or radiotherapy.
People whose general physical health and ability to carry out daily activities is rated as fully active or restricted in strenuous activity but able to do light work (confirm with trial site).
People whose liver function falls within a specific scoring range indicating reasonably well-preserved liver function (confirm with trial site).

Who may not be able to join:

People who have had another type of cancer within the past 5 years.
People whose medical records are incomplete.
People who have been followed up by their medical team for less than 3 months.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 6 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Guangxi Medical University

Registry

ClinicalTrials.gov

Start date

1 January 2019

Est. completion

31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Overall survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov